Twist Bioscience Corporation

NASDAQ:TWST

Medical - Diagnostics & Research

Healthcare
$116.35 +2.59%

+$2.15 today

Market cap
$7.66B
Beta
2.21
P/E (TTM)
-64.5
EPS (TTM)
-$1.32
52W Low $23.30High $88.46

Volume 2.23M

Average 1.53M

TWST Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Twist Bioscience CorporationNASDAQ: TWST

Net Income · Q4 FY2026 · quarter ended Sep 2026

Net income dips below year-ago levels

Q4 FY2026 net income of $20.62M (cash outflow) fell 24.0% year over year, behind the +67.6% change in trailing-twelve-month net income. Sequentially, it fell 41.2% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.

Context

  • Net income amounted to 28.3% of revenue in FY2026, up 7.7 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 8 analysts of -$85.27M (-34.5%) for the fiscal year ending Sep 2027, a slowdown from the +67.6% reported in FY2026.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$20.62M-41.2% QoQ
Last fiscal yearSep 2026
-$130.2M+67.6% YoY
LTMSep 2026
-$130.2M+67.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.0%-25.6%-1.6 pp
1 year+67.6%-34.5%-102.1 pp
3-year CAGR-14.0%-68.5%-54.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2026
(130.2M) USD
Year-over-year change
-67.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TWST compares with its peers on the latest reported figures

  • TWST's LTM Sep 2026 net income of $130.2M is the largest of the 2 companies compared; the peer median is $41.54M.
  • Its year-over-year change of +67.6% is the lowest of 2, against a peer median of +400.4%.
  • Net income amounts to 28.3% of revenue for TWST, versus a peer median of 5.3%.
TWST Competitors Peer median
Net Income for TWST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TWSTTwist Bioscience CorporationLTM Sep 2026$130.2M +67.6%-14.0%28.3%
RGENRepligen CorporationLTM Jun 2026$41.54M +400.4%-35.9%5.3%
Peer median (excluding TWST) $41.54M+400.4%-35.9%5.3%

Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Net Income(217.86M)(204.62M)(208.73M)(77.67M)(130.2M)
Depreciation & Amortization16.51M29.31M31.43M24.85M26.48M
Deferred Income Tax0(410K)000
Stock-Based Compensation79.66M30.28M50.93M64.46M69.86M
Change in Working Capital(5.36M)(1.01M)15.41M(12.61M)(7.83M)
Accounts Receivables(9.62M)(4.32M)8.44M(22.38M)(13.8M)
Inventory(7.54M)7.24M7.99M(4.23M)(18.1M)
Accounts Payables7.38M(2.51M)(11.81M)9.33M13.93M
Other Working Capital4.42M(1.42M)10.79M4.67M10.14M
Other Non-Cash Items2.66M3.98M46.86M(46.66M)265K
Operating Cash Flow(124.39M)(142.47M)(64.09M)(47.63M)(41.43M)
Capital Expenditures(101.86M)(27.78M)(5.08M)(28M)(47.58M)
Acquisitions (Net)(8.16M)5.86M02.5M0
Purchases of Investments(217.64M)(76.35M)(51.91M)(49.39M)(47.9M)
Sales of Investments100.48M154.74M53.91M50.14M49.35M
Other Investing Activities(5.76M)(5.86M)00(6.95M)
Investing Cash Flow(232.93M)50.61M(3.07M)(24.76M)(53.09M)
Debt Repayment(1.56M)0000
Common Stock Issued269.82M0013.56M446.72M
Common Stock Repurchased(7.75M)(4.41M)(3.98M)(16K)(42K)
Dividends Paid00000
Other Financing Activities10.02M5.32M10.87M15M0
Financing Cash Flow270.53M911K6.89M28.54M446.68M
Effect of Forex Changes(319K)(27K)126K583K24K
Net Change in Cash(87.1M)(90.98M)(60.15M)(43.27M)352.18M
Free Cash Flow(226.24M)(170.25M)(69.17M)(75.63M)(89.01M)

Twist Bioscience Corporation

NASDAQ:TWST

Intrinsic Alpha fair value

Locked

Current Price

$116.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.